https://doi.org/10.55788/2568befe
According to previous research, prevalence of functional respiratory complaints (FRCs) in the general population is approximately 8%. “Early reports after the SARS-CoV-2 outbreak suggested that hyperventilation syndrome was overrepresented in patients recovering from COVID-19, therefore, the aim of our study was to assess the prevalence of FRCs in COVID-19 survivors and to identify possible associated factors,” said Prof. Thomas Gille (Université Sorbonne Paris Nord, France) [1]. To understand the prevalence of FRCs following COVID-19 and identify potential contributing factors, a retrospective, observational, monocentric study was conducted. A total of 169 patients, including 100 men, participated in the study.
“The study included individuals who underwent pulmonary function tests at our centre in 2021, approximately 6.1 months after their COVID-19 episodes,” said Prof. Gille. A comprehensive assessment involved the completion of the Nijmegen questionnaire (NQ) and the Dyspnoea-12 questionnaire (D-12), which explored both the physical and psychological dimensions of dyspnoea. The study population was divided into 2 groups: the FRCs+ group (NQ score ≥23) and the no-FRCs group (NQ score ≤22).
Out of 169 patients, 25% were classified in the FRCs+ group, indicating a substantial prevalence of post-COVID-19 respiratory issues. Notably, 36% of the women fell into this category compared with 17% of the men (see Figure). This stark sex difference was statistically significant (P=0.004), highlighting a notable predominance in the occurrence of FRCs in women. Despite the observed sex difference, there was no significant disparity in mean age or BMI between the 2 groups; mean age was 57.8 years and mean BMI was 28.9 kg/m².
The presence of FRCs was strongly correlated with both the physical and affective dimensions of dyspnoea, as shown by the NQ and D-12 scores. Neither the time elapsed since the COVID-19 episode nor the results of the pulmonary function tests proved to be predictive factors for an NQ score ≥23, indicating that the persistence of respiratory complaints was not directly related to the severity of the initial infection.
In his conclusion, Prof. Gille underlined the significantly higher prevalence of post-COVID-19 FRCs compared with the general population, with women being disproportionately affected. These respiratory issues appeared to be independent of demographic characteristics but strongly correlated with the physical and affective dimensions of dyspnoea.
Figure: Presence of functional respiratory complaints in the general population and 6 months after a COVID-19 infection in the presented study [1]
- Gille T, et al. Prevalence and associated factors to post-COVID-19 functional respiratory complaints (FRCs) identified by the Nijmegen questionnaire. Abstract 4324, ERS 2023 Congress, 9–13 September, Milan, Italy.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Elevated myeloid inflammation and complement activation present in various phenotypes of long COVID Next Article
Women with pulmonary hypertension have better survival chances than men »
« Elevated myeloid inflammation and complement activation present in various phenotypes of long COVID Next Article
Women with pulmonary hypertension have better survival chances than men »
Table of Contents: ERS 2023
Featured articles
Letter from the Editor
Best of the Posters
sRAGE: A novel potential biomarker to assess the risk of acute respiratory events
Most severe asthma patients are candidates for biologic therapy on a global scale
Aspergillus infections: resistance to azole treatment increased in the presence of diesel particles
Asthma in 2023
Tapering from high-dose inhaled corticosteroids possible in most asthma patients treated with benralizumab
Tezepelumab therapy: hints toward a disease-modifying effect?
Digital inhaler programme improves asthma control also in the long term, but not long-term adherence
Respiratory health in children
Large infant study demonstrates the importance of a mature microbiome
Healthy maternal lifestyle during pregnancy reduces wheezing and rhinitis in infants
Mechanism of autophagy in a newborn responsible for deleterious effect of air pollutants
COPD: New Developments
Gabapentinoids increase risk of exacerbations in COPD
Future treatment of fatigue in COPD: 4 possible targets identified
Pulmonary Consequences of Long COVID
Women at higher risk of functional respiratory complaints following a COVID-19 infection
Elevated myeloid inflammation and complement activation present in various phenotypes of long COVID
Pulmonary Arterial Hypertension (PAH): Novel Developments
Encouraging long-term outcomes observed in the treatment of PAH with sotatercept
Chronic thromboembolic pulmonary hypertension: surgery entails encouraging long-term results
Women with pulmonary hypertension have better survival chances than men
Rare Diseases in 2023
Primary ciliary dyskinesia: Idrevloride shows promising results in phase 2 trial
Promising new agent as treatment for pulmonary fibrosis
Novel immunomodulator offers hope to reduce steroid dependency in sarcoidosis
Other Research of Interest
Tacrolimus versus cyclosporin: Less lung graft dysfunction
CPAP effective in reducing cardiovascular mortality in a practice study
Gefapixant curbs chronic cough independent of its duration
Related Articles
November 28, 2019
Pneumococcal vaccines: an effective way to reduce COPD hospitalisations
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com